BioCardia (NASDAQ:BCDA) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of BioCardia (NASDAQ:BCDA) to a sell rating in a research report report published on Saturday.

A number of other research analysts have also weighed in on the company. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of BioCardia in a report on Tuesday, June 9th. Zacks Research downgraded BioCardia from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $25.00.

BioCardia Price Performance

BCDA opened at $0.83 on Friday. BioCardia has a fifty-two week low of $0.78 and a fifty-two week high of $2.42. The firm has a market capitalization of $9.39 million, a PE ratio of -0.91 and a beta of 0.44. The company’s 50-day moving average is $0.97 and its 200 day moving average is $1.14.

BioCardia (NASDAQ:BCDA) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). As a group, analysts expect that BioCardia will post -0.76 EPS for the current year.

Insider Activity at BioCardia

In related news, Director Simon H. Stertzer purchased 39,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were bought at an average cost of $1.00 per share, with a total value of $39,000.00. Following the acquisition, the director owned 166,338 shares of the company’s stock, valued at $166,338. This represents a 30.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders acquired 146,900 shares of company stock worth $140,092. Insiders own 17.40% of the company’s stock.

Institutional Trading of BioCardia

A number of large investors have recently added to or reduced their stakes in the stock. Cetera Investment Advisers purchased a new position in BioCardia in the second quarter valued at about $40,000. Geode Capital Management LLC grew its position in shares of BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after acquiring an additional 27,263 shares during the period. Finally, DRW Securities LLC purchased a new stake in shares of BioCardia during the 4th quarter worth approximately $72,000. Hedge funds and other institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.